Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy.
Semaglutide just landed another win for peptide research. A new randomized, placebo-controlled trial shows that semaglutide slows down epigenetic aging in adults with HIV-associated lipohypertrophy. This isn’t just about fat loss or glucose control anymore — researchers dug deeper, running DNA methylation tests before and after 32 weeks of semaglutide.
Nat Commun
by Corley MJ, Dwaraka VB, Pang AP et al.
“Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. Corley MJ(1), Dwaraka VB(2), Pang AP(3), Labbato D(4), Smith R(2), Ross Eckard A(5), McComsey GA(6)(7). Author information: (1)University of California San Diego, Department of Medicine, Division of Geriatrics and Palliative Care, La Jolla, CA, USA. mjcorley@health.ucsd.edu. (2)TruDiagnostic, Lexington, KY, USA. (3)University of California San Diego, Department of Medicine, Division of Geriatrics and Palliative Care, La Jolla, CA, USA. (4)University Hospitals Cleveland Medical Center, Cleveland, OH, USA. (5)Medical University of South Carolina, Charleston, SC, USA. (6)University Hospitals Cleveland Medical Center, Cleveland, OH, USA. grace.mccomsey@uhhospitals.org. (7)Case Western Reserve University, Cleveland, OH, USA. grace.mccomsey@uhhospitals.org. Glucagon-like peptide-1 (GLP-1) receptor agonists have attracted interest as gerotherapeutics, yet clinical-trial evidence for their effects on biological aging is lacking. We report a post hoc exploratory epigenetic age analysis of a 32-week, randomized, double-blind, placebo-controlled phase 2b trial (NCT04019197) of semaglutide in adults with human immunodeficiency virus (HIV)-associated lipohypertrophy (semaglutide n = 45; placebo n = 39). The parent trial's primary endpoint was change in visceral adipose tissue, with secondary cardiometabolic and body-composition endpoints; epigenetic aging was not pre-specified. To address this gap, we profiled peripheral-blood DNA methylation (DNAm) at baseline and week 32 to assess semaglutide versus placebo on first-, second-, and third-generation epigenetic aging measures. In adjusted analyses, semaglutide reduced epigenetic aging across multiple second- and third-generation clocks, including PhenoAge ( - 4.9 years/year, p = 0.004), PCGrimAge ( - 3.1, p = 0.007), GrimAge V2 ( - 2.3, p = 0.009), OMICmAge ( - 2.2, p = 0.009), RetroAge ( - 2.2, p = 0.030), and DunedinPACE ( - 0.09 units, 9% slower, p = 0.01). Systems-based clocks showed parallel reductions in inflammation, brain, and heart aging measures. The post hoc design, modest sample size, HIV-specific cohort, and 32-week follow-up limit generalizability. Prospective trials are needed to determine whether GLP-1 receptor agonists can be repurposed as gerotherapeutics. © 2026. The Author(s). Conflict of interest statement: Competing interests: G.A.M. serves as a research consultant for Merck, GlaxoSmithKline/ViiV, and Gilead. M.J.C. serves as a scientific advisor for TruDiagnostic. V.D. and R.S. are employees of TruDiagnostic. All other authors declare no competing interests.”
What stands out: Semaglutide isn’t just tweaking metabolic markers. It’s dialing back biological age, at least according to several second- and third-generation epigenetic clocks. These clocks aren’t crystal balls, but they’re the best tools we have for measuring how "old" your body really is at the molecular level.
Here’s what the numbers look like:
PhenoAge dropped by almost five years per year (statistically significant)
PCGrimAge fell by just over three years
GrimAge V2, OMICmAge, and RetroAge all shifted in the right direction
DunedinPACE showed a 9% slower pace of aging
The trial was small (n=45 for semaglutide, n=39 for placebo) and focused on a specific group: people living with HIV and dealing with fat redistribution. The researchers admit this limits how widely you can apply the findings. Still, these results are the first direct clinical-trial evidence showing a GLP-1 receptor agonist can slow epigenetic aging. That’s a big deal for anyone interested in peptides as research compounds for aging.
Key takeaway: Semaglutide is starting to look like more than just a metabolic modulator. It’s edging into the gerotherapeutics conversation with solid, measurable anti-aging effects in humans.
For more on this research compound, check out the semaglutide page. If you’re sourcing peptides for your next project, the vendor directory lists the top options. Peptide science keeps pushing forward — and semaglutide is one to watch.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.